Would you recommend the following article to a politician, an athlete, a business executive, or a scientist?

BiogenIdec, Elan Up on Drug Data Shares in BiogenIdec (BIIB:Nasdaq - news - research) and Elan (ELN:NYSE - news - research)rose early Monday after the companies released what they described as  quot;compelling quot; phase III test results for their multiple sclerosis drug Antegren.
